Global Syringe Pump Markets – $29.4 Billion – Forecast & Opportunities, 2027

April 13, 2021

Global Syringe Pump Market, By Type (Infusion Pump v/s Withdrawal Pump), By Application (ICU, Cardiac Surgery Units, Pediatric Units, Operating Theaters, Others), By End User (Hospitals & Clinics, Ambulatory Care Settings, Others), By Region, Forecast & Opportunities, 2027

The Global Syringe Pump Market stood at USD19.60 billion in value terms in 2020 and is expected to grow at a CAGR of 7.21% and reach USD29.40 billion by 2026.

The Global Syringe Pump Market is driven by the growing geriatric population suffering from various chronic diseases such as cancer, cardiovascular diseases, renal disorders, among others. This has drastically increased the number of patients and requirement for continuous monitoring of their health. This in turn is anticipated to positively impact the market growth during the next five years.

Additionally, growing number of surgical procedures performed is also expected to foster the growth of the Global Syringe Pump Market. Furthermore, increasing investments and new product launches by the key vendors operating in the market is expected to create lucrative opportunities for the growth of the market through 2026.

The Global Syringe Pump Market is segmented based on type, application, end-user, company, and region. Based on end-user, the market can be fragmented into hospitals & clinics, ambulatory care settings, and others. The hospitals and clinics segment accounted for 55.5% market share in 2020 and this is expected to further grow in the forecast period.

This can be attributed to hospitals’ considerable financial resources for buying innovative medical equipment for their patients. Additionally, large patient population coming to the hospitals coupled with the availability of skilled & trained professionals is further anticipated to fuel the growth of segment over the next few years.

Regionally, the Global Syringe Pump Market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa.

Among these, Asia-Pacific is expected to witness the highest growth in the overall syringe pump market owing to the improving healthcare infrastructure in the region. Additionally, growing geriatric population in the region which is suffering from different chronic diseases is further expected to spur the market growth through 2026.

Major players operating in the Global Syringe Pump Market include Becton, Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., Fresenius Kabi, ICU Medical, Inc., Medtronic plc, Moog Inc., Terumo Corporation, Nipro Corporation, and Mindray Medical International Limited.

The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new service developments.

Companies Mentioned

  • Becton, Dickinson and Company
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Fresenius Kabi
  • ICU Medical, Inc.
  • Medtronic plc
  • Moog Inc.
  • Terumo Corporation
  • Nipro Corporation
  • Mindray Medical International Limited

Key Target Audience:

  • Syringe pump manufacturers, suppliers, distributors, and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums, and alliances related to syringe pumps
  • Market research and consulting firms

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Report Scope:

Global Syringe Pump Market, By Type:

  • Infusion Pump
  • Withdrawal Pump

Global Syringe Pump Market, By Application:

  • ICU
  • Cardiac Surgery Units
  • Pediatric Units
  • Operating Theaters
  • Others

Global Syringe Pump Market, By End-User:

  • Hospitals & Clinics
  • Ambulatory Care Settings
  • Others

Global Syringe Pump Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • South America
  • Brazil
  • Argentina
  • Colombia
  • For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”